

Inhalation CDMO Market Analysis With Opportunity Segments

The Business Research Company's Inhalation CDMO Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

LONDON, GREATER LONDON, UK, June 28, 2024 /EINPresswire.com/ -- The inhalation contract development and manufacturing organization (CDMO) market size has shown robust growth,



Size, Trends, And Global Forecast 2024-2033

increasing from \$1.94 billion in 2023 to \$2.08 billion in 2024, at a compound annual growth rate (CAGR) of 7.1%. This growth can be attributed to factors such as the rising prevalence of respiratory disorders, growing demand for personalized medicine, increasing outsourcing by pharmaceutical companies, and the expansion of the biopharmaceutical industry.

The inhalation CDMO market size is expected to see strong growth in the next few years. It will grow to \$2.7 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%." *The Business Research*

"

Focus on Precision Medicine and Targeted Therapies Drives Market Expansion

The market is expected to continue its growth trajectory, reaching \$2.7 billion by 2028, with a CAGR of 6.8%. This growth will be fueled by advancements in precision medicine, targeted therapies for respiratory diseases, patient-centric solutions, global market expansion, emerging market opportunities, and regulatory support for inhalation drug development.

Explore comprehensive insights into the global inhalation

<u>CDMO market</u> with a detailed sample report: <u>https://www.thebusinessresearchcompany.com/sample_request?id=13864&type=smp</u>

Major Players and Technological Innovations

Company

Key companies such as Pfizer Inc., Merck KGaA, and Catalent Inc. are at the forefront of the market, focusing on strategic partnerships and technological advancements. For instance, Hovione partnered with H&T Presspart to develop the Sunrise Capsule-based Dry Powder Inhaler platform, enhancing drug delivery efficiency to the lungs.

Emerging Trends in Inhalation CDMO

Trends in the forecast period include increasing demand for digital health solutions, biologic inhalation therapies, sustainable inhaler technologies, and the integration of artificial intelligence (AI) and machine learning in drug development and delivery.

Market Segments

• Product Type: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler

• Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome,

Pulmonary Fibrosis

• Technology: Manual Inhalers (SMI), Digital Inhalers

• End User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical

Companies, Generic Pharmaceutical Companies, Other End-Users

Geographical Insights: North America Leads, Asia-Pacific Shows Fastest Growth

North America dominated the inhalation CDMO market in 2023, while Asia-Pacific is expected to be the fastest-growing region. Detailed regional dynamics and growth opportunities are covered in the comprehensive report.

Order your report now for swift delivery <u>https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report</u>

Inhalation CDMO Global Market Report 2024 from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

• Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Inhalation CDMO Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on inhalation CDMO market size, <u>inhalation</u> <u>CDMO market drivers and trends</u>, <u>inhalation CDMO market major players</u>, competitors' revenues, market positioning, and market growth across geographies. The inhalation CDMO market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company: Breast Cancer Drugs Global Market Report 2024 <u>https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report</u>

Dermatitis Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Diuretics Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/diuretics-drugs-global-market-report

About The Business Research Company

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information The Business Research Company Europe: +44 207 1930 708 Asia: +91 8897263534 Americas: +1 315 623 0293

Oliver Guirdham The Business Research Company +44 20 7193 0708 info@tbrc.info Visit us on social media: Facebook X LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/723633071

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.